// App-Quantinova.ai

Abstract 11692 : High-Sensitivity Cardiac Troponin and the Efficacy of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial

Researchers

Presenter

  • David D Berg

Principal Investigators

  • Marc S Sabatine

  • Naveed Sattar

  • Petr Jarolim

  • Paul WELSH

  • Pardeep S Jhund

  • Inder Anand

  • Rudolf A De Boer

  • Mikhail Kosiborod

  • Eileen O'Meara

  • Ann Hammarstedt

  • Anna Maria Langkilde

  • Daniel Lindholm

  • Mikaela Sjstrand

  • John J McMurray

  • David Morrow

Medical Centers

  • Saint Lukes Mid America Heart Institute, Kansas City, MO

  • ASTRAZENECA, M Lndal, Sweden

  • University of Minnesota, Minneapolis, MN

  • Cardiovascular Div, TIMI Study Group, Brigham and Women's Hosp, Boston, MA

  • UMCG, Groningen

  • BHF CARDIOVASCULAR RESEARCH CENTRE, Glasgow

  • UNIVERSITY OF GLASGOW, Glasgow

  • Medecine, Montreal Heart Institute, Montreal, Canada

  • BRIGHAM AND WOMENS HOSPITAL, Boston, MA

  • TIMI Study Group, Boston, MA

  • AstraZeneca Biopharmaceuticals

Locations

  • United States

  • Sweden

  • Netherlands

  • Ukraine

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Heart failure with reduced ejection fraction

Biomarkers

  • High-sensitivity cardiac troponin T

Drug/Treatment

  • Dapagliflozin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved